Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in Place




Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in Place

ISS states, “[T]he [current] board appears to be working to pay SVA shareholders their fair share of dividends, and to resume trading of the company’s shares, which are the two most pressing issues currently facing SVA shareholders.”

SINOVAC’s Board of Directors encourages shareholders to follow recommendations by ISS and Glass Lewis and VOTE the WHITE proxy card “AGAINST” the misguided proposals to remove the SINOVAC Board and appoint the Reconstituted Imposter Former Board Slate

Special Meeting of SINOVAC shareholders to be held on July 8, 2025

To learn more, visit: VoteSinovac.com

BEIJING–(BUSINESS WIRE)–The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has joined Glass, Lewis & Co. (“Glass Lewis”) in recommending that SINOVAC shareholders vote to KEEP the current SINOVAC Board in place by voting the WHITE proxy card “AGAINST” the election of the Reconstituted Imposter Former Board Slate at the upcoming Special Meeting of Shareholders (the “Special Meeting”).

The SINOVAC Board issued the following statement in response to ISS’ recommendation:

“We are thrilled that independent proxy advisors ISS and Glass Lewis recommended shareholders vote to KEEP SINOVAC’s current Board in place and OPPOSE the Reconstituted Imposter Former Board Slate. In making their recommendations, ISS and Glass Lewis both recognized the swift actions the current SINOVAC Board has taken to restore fairness and deliver value to SINOVAC’s rightful shareholders, and they have criticized the Imposter Former Board’s abject governance failures that robbed value from SINOVAC shareholders during its seven-year “de facto” tenure.

“The facts speak for themselves: over the past four months, the current SINOVAC Board has demonstrated its commitment to righting the wrongs of the Imposter Former Board. The current Board has declared a US$55.00 per common share special cash dividend and has continued to lay the groundwork for additional distributions, is working with NASDAQ to resume trading, and is launching a formal exploration of a future listing on the Stock Exchange of Hong Kong to promote liquidity and support shareholder value creation.

“In contrast, the Imposter Former Board, in close coordination with SAIF, Advantech/Prime Success (“Advantech/Prime”) and Vivo Capital (together, “the Dissenting Investor Group”), continue to attempt to derail our progress through misleading rhetoric, baseless claims and frivolous legal actions. Their self-serving objective is clear: regain control of SINOVAC and deprive common shareholders of their rightful dividend payments.

“We urge shareholders to follow the recommendations of both leading independent proxy advisory firms by voting AGAINST the election of the Reconstituted Imposter Former Board on the WHITE proxy card.”

Highlights from the ISS Report include¹ (emphasis added):

SUPERIORITY OF THE CURRENT BOARD

• “[T]he [current] board appears to be working to pay SVA shareholders their fair share of dividends, and to resume trading of the company’s shares, which are the two most pressing issues currently facing SVA shareholders.”

DIVIDEND PAYMENTS

• “In engagement with ISS, when [the dissident’s] nominees who were former board members were asked why they did not pay dividends to SVA shareholders when they were board members, they gave several answers. […] However, neither reason is reflected in the company’s statements in its annual report for 2023, in which it states that the company ‘has no intention to distribute dividends in the near future.’ When the available facts outlined in the sections above are taken into account, it is difficult to rationalize the conduct of the former board with regard to dividend distributions to SVA shareholders.”
• “The former board […] presided over transactions that enabled the payment of billions of dollars in dividends to minority shareholders of SLS, all while it told SVA shareholders that it had no plans to pay dividends to them.”

POISON PILL AND NASDAQ TRADING HALT

• “It appears that the former board used the poison pill as an entrenchment mechanism. The former board declared that it had been triggered over one year prior, and acted to issue shares accordingly. In doing so, it appears that the former board was using it against shareholders who had cast more votes for their candidates at the 2018 AGM than had been cast for management nominees. In that sense, it appears that the former board was using the pill to overturn the will of a majority of shareholders.”
• “During this contest, the dissident has not provided a convincing explanation for why the former board could not remove the trading halt.”
• “[…] the more than decade-long record of former board members on the dissident slate paints a picture of a board that adopted and triggered a poison pill to disenfranchise shareholders, which led to the trading halt of the company’s shares.”

IMPOSTER FORMER BOARD’S SELF-DEALING

• “Shareholders can reasonably question whether the former SVA board acted appropriately in its appointment of SLS board members, who presumably approved the sale of nearly 41 percent of the entity at a time when SLS was generating healthy profits.”

At the Special Meeting, shareholders will have the chance to send a clear message to the Dissenting Investor Group: SINOVAC will no longer be held captive to their self-dealing.

SINOVAC’s Board urges shareholders to protect their investment and the future of their Company by voting the WHITE proxy card today “AGAINST” Proposals 1 and 2 at the Special Meeting.

For more details on the misdeeds and shareholder harm caused by the Imposter Former Board and Dissenting Investor Group, visit our website www.votesinovac.com.

Your Vote is Important

Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment.

We urge you to keep SINOVAC’s Board in place and vote on the WHITE proxy card “AGAINST” Proposal 1 to remove the current Board and “AGAINST” Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders.

DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count!

The Special Meeting of Shareholders will be held on Wednesday, July 9, 2025, at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025, at 8:00 p.m. Atlantic Standard Time). Valid shareholders of record as of the close of business on May 19, 2025, are entitled to vote at the meeting.

If you have any questions about locating your control number or voting your shares, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@georgeson.com.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under “Category 1 Preventative Biological Products” and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government’s vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

Important Additional Information and Where to Find It

In connection with SINOVAC’s Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission (“SEC”) and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC’s website, www.sec.gov, or from SINOVAC at its website: https://www.sinovac.com/en-us/Investors/sec_filings. You may also obtain copies of SINOVAC’s definitive proxy statement and other documents, free of charge, by contacting SINOVAC’s Investor Relations Department at ir@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s or Board’s control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Contacts

Investor and Media
FGS Global

Sinovac@fgsglobal.com

Bioscience Association Manitoba Applauds Government Action to Advance Bioscience Research and Clinical Trials in Manitoba




Bioscience Association Manitoba Applauds Government Action to Advance Bioscience Research and Clinical Trials in Manitoba

WINNIPEG, Manitoba–(BUSINESS WIRE)–Bioscience Association Manitoba (BAM) welcomes the Manitoba government’s latest announcement to launch a Clinical Trials Office, and the implementation of the Research Manitoba led project, Research Improvements Through Harmonization in Manitoba (RITHIM), both designed to accelerate and improve health research in the province.

“For too long, the process of moving innovative research into real-world care has taken longer in Manitoba than in other jurisdictions,” said Andrea Ladouceur, President & CEO of BAM. “Both the new Manitoba Clinical Trials Office and RITHIM are key pieces of the puzzle that will help connect research to our ecosystem and shorten timelines and enables research to get where it’s needed, into the lives of Manitobans.”

Manitoba has led with action on the top 2 recommendations from the Manitoba Clinical Trials Working Group. The first is to create a Clinical Trials office to champion connections between researcher and resources and the second is to create a timebound standardized processes.

BAM was honoured to co-chair this Working Group over the past 10 months developing recommendations to improve how research is conducted in the province.

The new Manitoba Clinical Trials Office, announced by Honourable Jamie Moses, Minister of Business, Mining, Trade, and Job Creation, will help champion Manitoba as a destination for world-class clinical research. RITHIM will also help shorten process timelines. Learn more at https://biomb.ca/manitoba-clinical-trails/.

“Clinical trials are essential to getting new, innovative medicines into our healthcare system,” noted Ladouceur. “Canada uses only about 20 per cent of the innovative medicines available in other G7 countries. Manitoba can and should lead the way in changing that.”

The bioscience sector contributes approximately 7 per cent of Manitoba’s GDP, with medicine ranked as the province’s top export. Manitoba is home to a growing hub of companies like Bausch Health, Pfizer, Cytophage Technologies, Emergent, Kane Biotech, and Dynacare, which are developing solutions that help patients return to healthier lives.

“Our members are leaders in how we heal, feed, and fuel the world,” said Ladouceur. “But innovation only matters if it reaches people. Many patients can’t wait for life-saving treatments. That’s why we need to continuously improve how we move research from the lab into people’s lives,” noted Andrea.

With this announcement, BAM sees Manitoba taking a strong step forward toward a more coordinated, responsive, and globally competitive research environment.

“We’re proud to support this important milestone,” added Ladouceur. “Manitoba is the right place for research to thrive with strong values around inclusivity, a commitment to quality, and a collaborative mindset. We look forward to what comes next.”

For more information about this announcement, visit https://news.gov.mb.ca/news/index.html?item=69639&posted=2025-07-02.

About Bioscience Association Manitoba

Bioscience Association Manitoba (BAM) is a not-for-profit industry association that enables commercial success for bioscience companies in Manitoba by acting as a catalyst for innovation, leading with one unified voice for all bioscience advancement and growth, and supporting a future-focused workforce.

Learn more about Bioscience Association Manitoba: https://biomb.ca/

Contacts

For additional details or media inquiries, please contact:
Chloe Gerrard – Communications & Marketing Manager, BAM

Email: chloe@biomb.ca

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)




Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 2, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 35,607 shares of common stock and 29,571 restricted stock units (“RSUs”) to seventeen new employees under Acadia’s 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price per share equal to $21.24 per share, Acadia’s closing trading price on July 2, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with Acadia through the applicable vesting dates. The RSUs will vest over four years, with 50% of the underlying shares vesting on the second anniversary of the grant date, and the balance of the underlying shares vesting in two equal annual installments measured from the second anniversary of the grant date, subject to the new employees’ continued service relationship with Acadia through the applicable vesting dates. The awards are subject to the terms and conditions of Acadia’s 2024 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neurological and rare diseases to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at Acadia.com and follow us on LinkedIn and X.

Contacts

Investor Contact:
Acadia Pharmaceuticals Inc.

Al Kildani

(858) 261-2872

ir@acadia-pharm.com

Acadia Pharmaceuticals Inc.

Jessica Tieszen

(858) 261-2950

ir@acadia-pharm.com

OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma




OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

• Company will be seeking alignment to begin rolling BLA submission

NEW YORK–(BUSINESS WIRE)–OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced it was granted an End of Phase 2 Meeting by the United States Food & Drug Administration (“FDA”) to review the OST-HER2 program in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma. The Company expects the meeting to occur in the third quarter of 2025. The End of Phase 2 Meeting marks a pivotal point in the drug development process, and a significant milestone towards market access.

The Company intends to seek alignment with FDA to begin a Rolling Review process for the forthcoming Biologics Licensing Application (“BLA”) submission for OST-HER2. The Rolling Review process means that a company can submit completed sections of its Biologic License Application (BLA) for review by FDA, rather than waiting until every section of the BLA is completed before the entire application can be reviewed. This can contribute to augmented interactions with FDA and potentially an expedited BLA approval timeline.

OST-HER2 has received FDA Orphan Disease Designation (ODD), Fast Track and Rare Pediatric Disease Designation (RPDD) from FDA. Under the RPDD program, if the Company receives Accelerated Approval prior to September 30, 2026, it will become eligible to receive a Priority Review Voucher (PRV) that it intends to sell. The most recent PRV sale, valued at $160 million, occurred in June 2025.

OST-HER2, an immunotherapy for osteosarcoma that uses a HER2-bioengineered form of the bacterium Listeria monocytogenes to trigger a strong immune response against HER2-expressing cancer cells, is featured in the movie Shelter Me: The Cancer Pioneers. The movie offers a look into canine comparative oncology, a field that compares treatment of cancers in dogs to those in people and covers developing treatments for rare forms of cancer. The trailer is available here and the movie is available via streaming on PBS’ website.

The most recent data regarding the OST-HER2 canine osteosarcoma program is available at this link. The Company has formed subsidiary OS Animal Health to advance the canine osteosarcoma program.

About OS Therapies

OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food & Drug Administration and Fast-Track and Orphan Drug designations from the US FDA and European Medicines Agency. The Company positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.

In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company’s proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and other risks and uncertainties described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s most recent Annual Report on Form 10-K and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

OS Therapies Contact Information:

Jack Doll

410.297.7793

Irpr@ostherapies.com

https://x.com/OSTherapies
https://www.instagram.com/ostherapies/
https://www.facebook.com/OSTherapies/
https://www.linkedin.com/company/os-therapies/

Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release




Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release

CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2025 on Wednesday, August 6, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 6, 2025.

Participating in the conference call will be:

Robert P. Mauch, President & Chief Executive Officer

James F. Cleary, Executive Vice President & Chief Financial Officer

The live call will be webcast via the Company’s website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.

To access the call via telephone from within the United States and Canada, dial +1 (833) 470-1428. From outside the United States and Canada, dial +1 (404) 975-4839. The access code for the call will be 015103.

Replays of the call will be made available via telephone and webcast. A replay of the webcast will be posted on investor.cencora.com approximately one hour after the completion of the call and will remain available for one year. The telephonic replay will also be available approximately one hour after the completion of the call and will remain available for 7 days. To access the telephonic replay from within the United States and Canada, dial +1 (866) 813-9403. From outside the United States, dial +1 (929) 458-6194. The access code for the replay is 676245.

Please check the website investor.cencora.com for updates regarding the timing of the live webcasts and for replay information.

About Cencora

Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. Cencora partners with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on Cencora for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Cencora’s 51,000+ worldwide team members contribute to positive health outcomes through the power of Cencora’s purpose: Cencora is united in its responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $290 billion in annual revenue. Learn more at investor.cencora.com.

Contacts

Bennett S. Murphy
Senior Vice President, Head of Investor Relations and Treasury
Bennett.Murphy@cencora.com

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)




Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company’s Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 175,000 shares of the company’s common stock to one new employee (the “Inducement Grant”) on July 1, 2025 (the “Grant Date”). The Inducement Grant has been granted outside of the company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remains subject to the terms and conditions of such Plan. The Inducement Grant was granted as an inducement material to the individual entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grant has an exercise price per share that is equal to the closing price of Viridian’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to the employee’s continued employment with Viridian through the applicable vesting dates.

About Viridian Therapeutics

Viridian is a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Both THRIVE and THRIVE-2 reported positive topline data, meeting all the primary and secondary endpoints of each study. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED.

In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on LinkedIn and X.

Contacts

IR@viridiantherapeutics.com
Media@viridiantherapeutics.com

Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model




Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model

ERLANGEN, Germany & BERLIN–(BUSINESS WIRE)–The novel compound AC102 almost completely reversed tinnitus in a preclinical model after a single dose. At the same time, the damaged connections between the auditory nerve and inner ear sensory cells were restored. These findings were recently published in the prestigious International Journal of Molecular Sciences in a joint study conducted by Erlangen University Hospital and Berlin-based drug developer AudioCure. As there is currently no causal treatment for tinnitus, there is a high medical need.

In the current study, AC102 was administered to the middle ear of one experimental group after acoustic trauma, while a second group received a placebo. Although both groups initially showed signs of tinnitus, they nearly disappeared in the AC102 group after five weeks – in clear contrast to the placebo group. Additionally, the AC102 group showed significantly less loss of synaptic connections between the inner ear and the auditory nerve than the placebo group. This damage is considered to be a potential cause of tinnitus: “Our results suggest regeneration of inner ear structures that are critical for tinnitus and could be an important milestone and a glimmer of hope for a causal treatment of tinnitus,” says the study’s first author, Dr. Konstantin Tziridis from Erlangen University Hospital.

About two-thirds of sudden hearing loss patients also suffer from tinnitus, which persists in around 30% of cases. Although 10-15% of adults experience tinnitus, no effective causal treatment exists. AC102 has the potential to become a new treatment option. In a preclinical acoustic trauma model, it almost completely reversed sudden hearing loss. Since tinnitus often accompanies sudden hearing loss, AudioCure is investigating AC102’s potential efficacy also against tinnitus in its ongoing study. AudioCure’s CEO, Dr. Reimar Schlingensiepen, emphasizes: “Constant ear noise caused by tinnitus can be even more stressful for many patients than the hearing loss itself. With AC102, we hope to eventually have an effective remedy for both conditions. This would be a great relief for patients and doctors who have no approved drug treatment available at present.” AC102 has already been tested for safety and tolerability in a clinical study and is currently being examined in a Europe-wide Phase-2-study in patients for its effectiveness in sudden hearing loss and tinnitus.

Contacts

AudioCure Pharma GmbH

Frauke Luers

Phone: +49 30 2218 397-0

E-Mail: pr@ac-clinical.com
Web: www.audiocure.com

Biosynth Expands Berlin Site with a New Commercial Bioconjugation Suite




Biosynth Expands Berlin Site with a New Commercial Bioconjugation Suite

The new suite extends GMP bioconjugate production for intermediates and active pharmaceutical ingredients from early clinical phase through to late clinical phases and commercial supply.

STAAD, Switzerland–(BUSINESS WIRE)–Biosynth, a leading developer and supplier of critical raw materials and services for life sciences and diagnostics, is pleased to announce the opening of its expanded GMP bioconjugation facility at its existing Berlin site. This strategic expansion significantly enhances Biosynth’s specialized manufacturing capabilities in conjugate vaccines and conjugate drugs, activated PEGs, and polymer-based drug delivery excipients as part of its global manufacturing network.

Thomas Eisele, Chief Operations Officer, stated, “We are thrilled to officially open the new expansion to our bioconjugation facility in Berlin, which represents a significant enhancement to our existing operations. This suite enables the scalable, diverse, high-quality conjugation services that our customers need to advance to the next generation of therapies.”

Frank Leenders, General Manager for the Berlin site, commented, “The construction of our new facility, including class D and C cleanrooms, represents a natural evolution of our Berlin operation—in many ways we are growing alongside our customers. The additional refurbishment of our existing facility enhances our GMP manufacturing capabilities, reinforcing our commitment to meeting the evolving needs of our customers.”

“Conjugation chemistry, advanced polymers and bioconjugation production are critical areas for many of our life science customers,” added Marie Leblanc, Executive Vice President, Life Sciences. “Being able to support projects fully, from initial bioconjugate process development to commercial GMP supply, enables us to provide specialized conjugation solutions for diagnostics and therapeutics—strengthening our position as a trusted partner in the Life Science industry.”

About Biosynth

Biosynth is a leading supplier of critical raw materials and services for the life sciences industry. With a deep commitment to quality, Biosynth serves pharmaceutical, diagnostics and life sciences research customers through its global network of R&D and production sites. Headquartered in Switzerland, Biosynth partners with customers worldwide to accelerate innovation and ensure reliability at every stage of development and manufacturing. For more information, please visit www.biosynth.com.

Contacts

Media Contacts

Biosynth

Aimee Cossins

+44 7984 525560

marketing@biosynth.com

Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan




Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan

BAAR, Switzerland & OSAKA, Japan & TOKYO–(BUSINESS WIRE)–Stallergenes Greer, Shionogi & Co., Ltd. (“Shionogi”) and CEOLIA Pharma Co. Ltd (“CEOLIA”) today announced the transition of promotional activities for Actair® in Japan. Actair® is Stallergenes Greer’s sublingual immunotherapy tablet for the treatment of patients suffering from house dust mite induced allergic rhinitis.

After ending the license agreement established in 2010 with Shionogi, which had been responsible for developing, registering, and commercialising Actair® in Japan, Stallergenes Greer has appointed CEOLIA as its new promotional partner in the country starting July 3. To ensure the continuity of both patient care and support for healthcare professionals, Shionogi will continue during a transition period to serve as the Marketing Authorisation Holder (MAH) in Japan and remain responsible for the importation, manufacturing and distribution of Actair®. Shionogi will also provide active support to CEOLIA by transferring knowledge and offering operational assistance.

Stallergenes Greer acknowledges Shionogi’s contribution and sustained commitment to improving allergy care in Japan. The company welcomes CEOLIA as a trusted new partner and looks forward to working closely together to further advance access to allergen immunotherapy treatments and continue to improve the quality of life of patients with respiratory allergies.

ABOUT STALLERGENES GREER

Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries.

For more information, visit www.stallergenesgreer.com.

ABOUT SHIONOGI & Co. Ltd

Shionogi has identified “Contributing to a Healthy and Prosperous Life” as one of its key material issues. The group is committed to building a society where everyone can live vibrantly and true to themselves. With a continued focus on areas of high unmet medical needs, Shionogi strives to deliver innovative treatments that improve the quality of life (QOL) for patients and their families.

For more information, visit https://www.shionogi.com/jp/ja/

ABOUT CEOLIA

CEOLIA, founded in 2010, is a pharmaceutical company dedicated to serving all healthcare needs in the otolaryngology (ENT) field. With a mission and philosophy to serve and contribute to people’s health and happiness, we develop and manufacture and market ethical drugs, medical devices, and diagnostic reagents in the ENT field. For more information, visit https://www.ceolia.co.jp/.

Contacts

Stallergenes Greer

Communications

Catherine Kress

Tel: +33 (0)1 55 50 26 05

Email: catherine.kress@stallergenesgreer.com

Shionogi

SHIONOGI Website Inquiry Form: www.shionogi.com/global/en/contact

CEOLIA

Tel: +81 3 3243 1135

CEOLIA Website enquiry form: www.ceolia.co.jp/en/contact/enquiry_form

Token Calls Out Another Preventable Breach: Hawaiian Airlines Attack Echoes Aflac, Underscores Need for Phishing-Proof MFA




Token Calls Out Another Preventable Breach: Hawaiian Airlines Attack Echoes Aflac, Underscores Need for Phishing-Proof MFA

ROCHESTER, N.Y.–(BUSINESS WIRE)–#BioKey–In the wake of Hawaiian Airlines’ disclosure of a cybersecurity incident that disrupted internal IT systems, Token, the leader in biometric, passwordless authentication, issued a stark reminder: this breach, like others before it, was entirely preventable.

Security researchers suspect the same threat group, Scattered Spider, is behind the attack—relying again on real-time phishing and spoofed websites to bypass weak multi-factor authentication (MFA) like push approvals and authenticator apps.

“These aren’t sophisticated attacks,” said Kevin Surace, Chair of Token. “They’re simple relays, executed through fake websites. And they work because companies are still trusting outdated MFA like TOTP codes or app prompts or authentication apps. Hawaiian Airlines just joined a growing list that includes insurers, retailers, and airlines—because legacy authentication is no match for modern phishing.”

Token’s products—Token Ring and Token BioStick—are purpose-built to stop these attacks dead in their tracks.

Why Token Stops What Others Can’t

The breach playbook is now well known:

1. A spoofed website tricks an employee into logging in.
2. The attacker relays the credentials and MFA code to the real site (or tricks the employee into authorizing the attacker on their authentication application).
3. Access is granted—because the authentication method trusts the user, not the origin.

Token products don’t make that mistake.

Token uses biometric fingerprint verification, local cryptographic keys, and origin-checking to ensure only the legitimate user, on the right device, accessing the right site, locally, can log in.

“Even if an employee fell for the phishing link, Token would have blocked the login. The fake site simply wouldn’t pass the cryptographic check, and, in fact, the Token product would have never even been engaged, since proximity is required,” Surace added.

Unlike passkeys—which can be synced across cloud accounts and exploited through account takeovers—Token’s credentials are stored in tamper-proof hardware, tied to a specific domain, and can only be unlocked with a live biometric scan local to the computer logging in. That means no code to intercept, no password to steal, and no cloud account to hijack.

Proven in the Real World

Just days ago, Token warned the industry after the Aflac breach that the use of weak MFA continues to leave companies wide open to phishing attacks. Now, Hawaiian Airlines finds itself in the same position.

“How many breaches do we need before we replace security theater with real security?” Surace asked. “Token isn’t just another MFA solution. It’s phishing-proof, fool-proof, and deployable in a single day.”

About Token

Token’s mission is to eliminate identity-based attacks with the world’s strongest authentication. Token Ring and Token BioStick provide true passwordless, biometric MFA that cannot be phished, replayed, relayed or spoofed. Built on FIDO2 biometric standards, Token is trusted by organizations where security failures are not an option.

For more information, visit www.tokenring.com.

Contacts

Media Contact:
Dan Chmielewski

Madison Alexander PR

949-231-2965

dchm@madisonalexanderpr.com